{"title":"亚裔、夏威夷原住民和太平洋岛民亚群妇女中主要 CYP2C19 基因多态性的频率。","authors":"Khalifa Y Alrajeh, Youssef M Roman","doi":"10.2217/pme-2021-0175","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Prevalence of clinically actionable genetic variants of <i>CYP2C19</i> is lacking in specific population subgroups. This study aims to assess the frequencies of <i>CYP2C19*2</i>, <i>*3</i>, and <i>*17</i> in Asian, Native Hawaiian and Pacific Islander (NHPI) population subgroups compared with Europeans. <b>Patients & methods:</b> The study included repository DNA samples of 1064 women, 18 years or older, who self-reported as Filipino, Korean, Japanese, Native Hawaiian, Marshallese and Samoan. <b>Results:</b> The overall frequencies of <i>CYP2C19*2</i> (25-36%) and <i>CYP2C19*3</i> (2.5-10%) were significantly higher in all our subgroups than in Europeans (15 and 0.02%, respectively). The overall frequency of <i>CYP2C19*17</i> was significantly lower in all our subgroups (1-6%) than in Europeans (21.7%). <b>Conclusion:</b> This is the first report on the frequencies of <i>CYP2C19*2</i>, <i>*3</i>, and <i>*17</i> in women of Asian and NHPI descent with distinct population subgroup differences. Differential allele frequencies of <i>CYP2C19</i> among population subgroups underscore the importance of increasing racial and ethnic diversity in pharmacogenetic research.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"19 4","pages":"327-339"},"PeriodicalIF":1.7000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318053/pdf/pme-19-327.pdf","citationCount":"0","resultStr":"{\"title\":\"The frequency of major <i>CYP2C19</i> genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups.\",\"authors\":\"Khalifa Y Alrajeh, Youssef M Roman\",\"doi\":\"10.2217/pme-2021-0175\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Prevalence of clinically actionable genetic variants of <i>CYP2C19</i> is lacking in specific population subgroups. This study aims to assess the frequencies of <i>CYP2C19*2</i>, <i>*3</i>, and <i>*17</i> in Asian, Native Hawaiian and Pacific Islander (NHPI) population subgroups compared with Europeans. <b>Patients & methods:</b> The study included repository DNA samples of 1064 women, 18 years or older, who self-reported as Filipino, Korean, Japanese, Native Hawaiian, Marshallese and Samoan. <b>Results:</b> The overall frequencies of <i>CYP2C19*2</i> (25-36%) and <i>CYP2C19*3</i> (2.5-10%) were significantly higher in all our subgroups than in Europeans (15 and 0.02%, respectively). The overall frequency of <i>CYP2C19*17</i> was significantly lower in all our subgroups (1-6%) than in Europeans (21.7%). <b>Conclusion:</b> This is the first report on the frequencies of <i>CYP2C19*2</i>, <i>*3</i>, and <i>*17</i> in women of Asian and NHPI descent with distinct population subgroup differences. Differential allele frequencies of <i>CYP2C19</i> among population subgroups underscore the importance of increasing racial and ethnic diversity in pharmacogenetic research.</p>\",\"PeriodicalId\":19753,\"journal\":{\"name\":\"Personalized medicine\",\"volume\":\"19 4\",\"pages\":\"327-339\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318053/pdf/pme-19-327.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Personalized medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/pme-2021-0175\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/6/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/pme-2021-0175","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups.
Aim: Prevalence of clinically actionable genetic variants of CYP2C19 is lacking in specific population subgroups. This study aims to assess the frequencies of CYP2C19*2, *3, and *17 in Asian, Native Hawaiian and Pacific Islander (NHPI) population subgroups compared with Europeans. Patients & methods: The study included repository DNA samples of 1064 women, 18 years or older, who self-reported as Filipino, Korean, Japanese, Native Hawaiian, Marshallese and Samoan. Results: The overall frequencies of CYP2C19*2 (25-36%) and CYP2C19*3 (2.5-10%) were significantly higher in all our subgroups than in Europeans (15 and 0.02%, respectively). The overall frequency of CYP2C19*17 was significantly lower in all our subgroups (1-6%) than in Europeans (21.7%). Conclusion: This is the first report on the frequencies of CYP2C19*2, *3, and *17 in women of Asian and NHPI descent with distinct population subgroup differences. Differential allele frequencies of CYP2C19 among population subgroups underscore the importance of increasing racial and ethnic diversity in pharmacogenetic research.
期刊介绍:
Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape thefuture of medicine by providing a platform for expert commentary and analysis.
The journal addresses scientific, commercial and policy issues in the field of precision medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles.